The Jain Foundation
The Jain Foundation is an organization dedicated to addressing muscular dystrophies resulting from dysferlin protein deficiency. It focuses on supporting drug development and clinical trials aimed at finding effective treatments for these conditions. In addition to its research initiatives, the foundation has established a robust patient support and advocacy platform, ensuring that affected individuals and families have access to necessary resources and information. Through its comprehensive approach, the Jain Foundation aims to advance scientific understanding and improve the quality of life for those impacted by muscular dystrophies.
1 past transactions
Myonexus Therapeutics
Seed Round in 2017
Myonexus Therapeutics is a clinical stage company focused on developing gene therapies for rare diseases, specifically targeting Limb-girdle muscular dystrophy (LGMD) Types 2D, 2B, 2E, 2L, and 2C. The company is rooted in research conducted at Nationwide Children’s Hospital, which is recognized for its expertise in muscular dystrophy gene therapy and translational research. Myonexus aims to pioneer the first effective treatments for these specific LGMD types, utilizing advanced precision genetic medicine approaches. In addition to LGMD, the company’s innovative therapies show potential for addressing other genetic disorders, including Charcot-Marie-Tooth disease, MPS IIIA, and Pompe disease, among others.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.